A systematic review and meta-analysis of the success of blinding in antidepressant RCTs
- PMID: 34861421
- DOI: 10.1016/j.psychres.2021.114297
A systematic review and meta-analysis of the success of blinding in antidepressant RCTs
Abstract
Successful blinding in double-blind RCTs is crucial for minimizing bias, however studies rarely report information about blinding. Among RCTs for depression, the rates of testing and success of blinding is unknown. We conducted a systematic review and meta-analysis of the rates of testing, predictors, and success of blinding in RCTs of antidepressants for depression. Following systematic search, further information about blinding assessment was requested from corresponding authors of the included studies. We reported the frequency of blinding assessment across all RCTs, and conducted logistic regression analyses to assess predictors of blinding reporting. Participant and/or investigator guesses about treatment allocation were used to calculate Bang's Blinding Index (BI). The BI between RCT arms was compared using meta-analysis. Across the 295 included trials, only 4.7% of studies assessed blinding. Pharmaceutical company sponsorship predicted blinding assessment; unsponsored trials were more likely to assess blinding. Meta-analysis suggested that blinding was unsuccessful among participants and investigators. Results suggest that blinding is rarely assessed, and often fails, among RCTs of antidepressants. This is concerning considering controversy around the efficacy of antidepressant medication. Blinding should be routinely assessed and reported in RCTs of antidepressants, and trial outcomes should be considered in light of blinding success or failure.
Keywords: Antidepressants; Blinding; Depression; Randomized controlled trials.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Antidepressants for people with epilepsy and depression.Cochrane Database Syst Rev. 2021 Apr 16;4(4):CD010682. doi: 10.1002/14651858.CD010682.pub3. Cochrane Database Syst Rev. 2021. PMID: 33860531 Free PMC article.
-
The Blind Leading the Not-So-Blind: A Meta-Analysis of Blinding in Pharmacological Trials for Chronic Pain.J Pain. 2019 May;20(5):489-500. doi: 10.1016/j.jpain.2018.09.002. Epub 2018 Sep 21. J Pain. 2019. PMID: 30248448
-
Antidepressants for the treatment of depression in people with cancer.Cochrane Database Syst Rev. 2015 Jun 1;2015(6):CD011006. doi: 10.1002/14651858.CD011006.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2018 Apr 23;4:CD011006. doi: 10.1002/14651858.CD011006.pub3. PMID: 26029972 Free PMC article. Updated. Review.
-
Antidepressants for people with epilepsy and depression.Cochrane Database Syst Rev. 2014 Dec 3;2014(12):CD010682. doi: 10.1002/14651858.CD010682.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2021 Apr 16;4:CD010682. doi: 10.1002/14651858.CD010682.pub3. PMID: 25464360 Free PMC article. Updated. Review.
-
Fluoxetine versus other types of pharmacotherapy for depression.Cochrane Database Syst Rev. 2013 Jul 17;(7):CD004185. doi: 10.1002/14651858.CD004185.pub3. Cochrane Database Syst Rev. 2013. PMID: 24353997 Review.
Cited by
-
Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.Sci Rep. 2024 Apr 17;14(1):8833. doi: 10.1038/s41598-024-58318-x. Sci Rep. 2024. PMID: 38632313 Free PMC article. Clinical Trial.
-
Treatment guesses in the Treatment for Adolescents with Depression Study: Accuracy, unblinding and influence on outcomes.Aust N Z J Psychiatry. 2024 Apr;58(4):355-364. doi: 10.1177/00048674231218623. Epub 2023 Dec 21. Aust N Z J Psychiatry. 2024. PMID: 38126083 Free PMC article.
-
Seeing Through the Blind: Belief About Treatment Randomization and Smoking Cessation Outcome Among People With Current or Past Major Depressive Disorder Who Smoke in a Placebo-Controlled Trial of Varenicline.Nicotine Tob Res. 2024 Apr 22;26(5):597-603. doi: 10.1093/ntr/ntad218. Nicotine Tob Res. 2024. PMID: 37934573 Clinical Trial.
-
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.Sci Rep. 2023 Jul 26;13(1):12107. doi: 10.1038/s41598-023-34938-7. Sci Rep. 2023. PMID: 37495637 Free PMC article.
-
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.J Psychopharmacol. 2023 Jul;37(7):649-659. doi: 10.1177/02698811231180276. Epub 2023 Jul 4. J Psychopharmacol. 2023. PMID: 37403379 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical